Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fadolmidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.59 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | UBA1 | P22314 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fadolmidine SCHEMBL1649867 | 0.97 | ESR1 (0.57) | ESR1ESR2NQO2MTNR1AMTNR1B | |
| SCHEMBL27387166 | 0.80 | HTR6 (0.50) | HRH4HTR3AHRH3CYP19A1 | |
| Fadolmidine SCHEMBL2641380 | 0.73 | ESR1 (0.59) | ESR1ESR2NQO2MTNR1AMTNR1B | |
| Fadolmidine SCHEMBL29365481 | 0.73 | ESR1 (0.59) | ESR1ESR2NQO2MTNR1AMTNR1B | |
| Fadolmidine SCHEMBL2641142 | 0.72 | ESR1 (0.58) | ESR1ESR2NQO2MTNR1AMTNR1B | |
| Fadolmidine SCHEMBL29489898 | 0.72 | ESR1 (0.58) | ESR1ESR2NQO2MTNR1AMTNR1B | |
| SCHEMBL11652411 | 0.71 | ESR1 (0.66) | ESR1ESR2NQO2MTNR1AMTNR1B | |
| SCHEMBL3411465 | 0.69 | ESR1 (0.62) | ESR1ESR2NQO2MTNR1AMTNR1B | |
| SCHEMBL11668110 | 0.68 | ESR1 (0.60) | ESR1ESR2NQO2MTNR1AMTNR1B | |
| SCHEMBL9628347 | 0.68 | ESR1 (0.60) | ESR1ESR2NQO2MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2025-06-12 | — | — | US | disclosed |
| US-20240065999-A1 | Ophthalmic Formulation Containing a Dopaminergic Prodrug that may be Combined with One or More Agents | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-02-29 | — | — | US | disclosed |
| WO-2023178183-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND ALPHA-2 ADRENERGIC RECEPTORS FOR TREATMENT OF STRESS INDUCED DEPRESSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-09-21 | — | — | WO | disclosed |
| US-8569312-B2 | Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569312-B2 | Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130225582-A1 | BIARYL-SPIROAMINOOXZAOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8501747-B2 | Functionally selective alpha2C adrenoreceptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501747-B2 | Functionally selective alpha2C adrenoreceptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8476274-B2 | Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476274-B2 | Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-02 | — | — | US | disclosed |
| WO-2010033495-A2 | FUNCTIONALLY SELECTIVE AZANITRILE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010017120-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | SCHERING CORPORATION (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2009105504-A2 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009020578-A1 | ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008100456-A2 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008100480-A1 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008100457-A2 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008100459-A1 | DERIVATIVES AND ANALOGS OF CHROMAN AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240065999-A1 | Ophthalmic Formulation Containing a Dopaminergic Prodrug that may be Combined with One or More Agents | SLC6A3, SLC18A2, SLC6A2 | ESR1 2438/4885ESR2 3481/4885NQO2 1174/4885 |
| US-20130225582-A1 | BIARYL-SPIROAMINOOXZAOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | ADRA2C, ADRB2, ADRA2A | ESR1 2234/4885ESR2 309/4885NQO2 1148/4885 |
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | GABRB2, GABRB1, ADRB2 | ESR1 1045/4885ESR2 201/4885NQO2 4125/4885 |
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | ESR1 1364/4885ESR2 289/4885NQO2 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.